KZR vs. TLSA, ELDN, IMMX, ANEB, CKPT, CALC, KRON, CARM, EQ, and EGRX
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Tiziana Life Sciences (TLSA), Eledon Pharmaceuticals (ELDN), Immix Biopharma (IMMX), Anebulo Pharmaceuticals (ANEB), Checkpoint Therapeutics (CKPT), CalciMedica (CALC), Kronos Bio (KRON), Carisma Therapeutics (CARM), Equillium (EQ), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical preparations" industry.
Tiziana Life Sciences (NASDAQ:TLSA) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
Tiziana Life Sciences has higher earnings, but lower revenue than Kezar Life Sciences.
Kezar Life Sciences received 38 more outperform votes than Tiziana Life Sciences when rated by MarketBeat users. However, 63.58% of users gave Tiziana Life Sciences an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
In the previous week, Kezar Life Sciences had 8 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 12 mentions for Kezar Life Sciences and 4 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.81 beat Kezar Life Sciences' score of 0.47 indicating that Kezar Life Sciences is being referred to more favorably in the news media.
67.9% of Kezar Life Sciences shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 7.9% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Tiziana Life Sciences has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
Kezar Life Sciences' return on equity of 0.00% beat Tiziana Life Sciences' return on equity.
Kezar Life Sciences has a consensus price target of $11.00, suggesting a potential upside of 1,332.29%. Given Tiziana Life Sciences' higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Tiziana Life Sciences.
Summary
Kezar Life Sciences beats Tiziana Life Sciences on 7 of the 13 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
